Cargando…

Beyond fludarabine: pentostatin plus cyclophosphamide are a well-tolerated alternative in reduced intensity conditioning

Detalles Bibliográficos
Autores principales:	Dimitrova, Dimana, Kanakry, Jennifer A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9715427/ https://www.ncbi.nlm.nih.gov/pubmed/36115868 http://dx.doi.org/10.1038/s41409-022-01819-y

Ejemplares similares

Bendamustine vs. fludarabine/cyclophosphamide lymphodepletion prior to BCMA CAR-T cell therapy in multiple myeloma
por: Sidana, Surbhi, et al.
Publicado: (2023)

Adverse Effects of Busulfan Plus Cyclophosphamide versus Busulfan Plus Fludarabine as Conditioning Regimens for Allogeneic Bone Marrow Transplantation
por: Mehdizadeh, Mahshid, et al.
Publicado: (2021)

Efflux capacity and aldehyde dehydrogenase both contribute to CD8(+) T-cell resistance to posttransplant cyclophosphamide
por: Patterson, Michael T., et al.
Publicado: (2022)

Sars-Cov-2 Infection and Vaccination in Recipients of Reduced-Intensity Conditioning, Posttransplantation Cyclophosphamide (PTCy)-Based Allogeneic Hematopoietic Cell Transplantation (HCT)
por: Dimitrova, Dimana, et al.
Publicado: (2022)

Ibrutinib plus fludarabine, cyclophosphamide and rituximab (iFCR) as initial treatment in chronic lymphocytic leukemia/ small lymphocytic leukemia with or without TP53 aberrations: a prospective real-world study in Chinese cohort
por: Miao, Yi, et al.
Publicado: (2023)

Extracorporeal Photopheresis in Addition to Pentostatin in Conditioning for Canine Hematopoietic Cell Transplantation: Role in Engraftment
por: Bethge, Wolfgang A., et al.
Publicado: (2010)

Fludarabine plus reduced-intensity busulfan versus fludarabine plus myeloablative busulfan in patients with non-Hodgkin lymphoma undergoing allogeneic hematopoietic cell transplantation
por: Kamijo, Kimimori, et al.
Publicado: (2023)

Fludarabine and cyclophosphamide provides a nonmyeloablative alternative conditioning regimen with low transplant-related mortality and control of high risk disease
por: Paplham, Pamela, et al.
Publicado: (2014)

Aplastic Anemia Preconditioned with Fludarabine, Cyclophosphamide, and Anti-Thymocyte Globulin
por: Yang, Dan, et al.
Publicado: (2019)

Extracorporeal photopheresis combined with pentostatin in the conditioning regimen for canine hematopoietic cell transplantation does not prevent GVHD
por: Bethge, Wolfgang, et al.
Publicado: (2014)

Reduced-toxicity myeloablative conditioning consisting of 8-Gy total body irradiation, cyclophosphamide and fludarabine for pediatric hematological malignancies
por: Hirabayashi, Koichi, et al.
Publicado: (2014)

Rituximab and Fludarabine or Cyclophosphamide Combination Treatment for Older Waldenström Macroglobulinemia Patients
por: Xu, XiaoWei, et al.
Publicado: (2013)

Decitabine in combination with fludarabine and cyclophosphamide as a lymphodepletion regimen followed by CD19/CD22 bispecific targeted CAR T-cell therapy significantly improves survival in relapsed/refractory B-ALL patients
por: Ma, Yunju, et al.
Publicado: (2023)

Obinutuzumab plus fludarabine and cyclophosphamide in previously untreated, fit patients with chronic lymphocytic leukemia: a subgroup analysis of the GREEN study
por: Bosch, Francesc, et al.
Publicado: (2019)

Relationship of iothalamate clearance and NRM in patients receiving fludarabine and melphalan reduced-intensity conditioning
por: Kutzke, Jade L., et al.
Publicado: (2022)

Cost-effectiveness of adding rituximab to fludarabine and cyclophosphamide for treatment of chronic lymphocytic leukemia in Ukraine
por: Mandrik, Olena, et al.
Publicado: (2015)

Cyclophosphamide/fludarabine/rituximab: Prolonged viral shedding and protracted COVID-19: case report
Publicado: (2022)

Low-grade lymphoma: Beyond fludarabine-single therapy
por: Park, Eunkyung
Publicado: (2011)

Fludarabine–Cyclophosphamide-Based Conditioning with Antithymocyte Globulin Serotherapy Is Associated with Durable Engraftment and Manageable Infections in Children with Severe Aplastic Anemia
por: Salamonowicz-Bodzioch, Małgorzata, et al.
Publicado: (2021)

Busulfan plus fludarabine as a myeloablative conditioning regimen compared with busulfan plus cyclophosphamide for acute myeloid leukemia in first complete remission undergoing allogeneic hematopoietic stem cell transplantation: a prospective and multicenter study
por: Liu, Hui, et al.
Publicado: (2013)

Fludarabine/Cyclophosphamide Conditioning Regimen in Aplastic Anemia Patients Receiving Matched-Sibling Donor Transplant Is Non-inferior to ATG/Cyclophosphamide: A Single-Center Experience from Pakistan
por: Zaidi, Uzma, et al.
Publicado: (2022)

ALL-RIC trial protocol: a comparison of reduced dose total body irradiation (TBI) and cyclophosphamide with fludarabine and melphalan reduced intensity conditioning in adults with acute lymphoblastic leukaemia (ALL) in complete remission
por: Marks, David I, et al.
Publicado: (2023)

Prediction of poor outcome in CLL patients following first-line treatment with fludarabine, cyclophosphamide and rituximab
por: Fink, A M, et al.
Publicado: (2013)

Allogeneic stem cell transplant for multiple myeloma & myelofibrosis with split-dose busulfan, fludarabine & cyclophosphamide
por: Trunk, Andrew D., et al.
Publicado: (2023)

Improved outcome of haploidentical transplantation in severe aplastic anemia using reduced-intensity fludarabine-based conditioning
por: Yamei, Wu, et al.
Publicado: (2017)

Reduced-Intensity Conditioning with Busulfan and Fludarabine for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Lymphoblastic Leukemia
por: Lee, Seung-Shin, et al.
Publicado: (2020)

Fludarabine-based myeloablative regimen as pretransplant conditioning therapy in adult acute leukemia/myelodysplastic syndrome: comparison with oral or intravenous busulfan with cyclophosphamide
por: Lee, Ji Hyun, et al.
Publicado: (2010)

Comparison of Conventional Cyclophosphamide versus Fludarabine-Based Conditioning in High-Risk Aplastic Anemia Patients Undergoing Matched-Related Donor Transplantation
por: Iftikhar, Raheel, et al.
Publicado: (2020)

A phase II Japanese trial of fludarabine, cyclophosphamide and rituximab for previously untreated chronic lymphocytic leukemia
por: Izutsu, Koji, et al.
Publicado: (2020)

Reduced Intensity Allogeneic Hematopoietic Cell Transplantation using Fludarabine-Melphalan conditioning for Treatment of Mature T-cell Lymphomas
por: Delioukina, Maria, et al.
Publicado: (2011)

Clofarabine versus fludarabine‐based reduced‐intensity conditioning regimen prior to allogeneic transplantation in adults with AML/MDS
por: Chevallier, Patrice, et al.
Publicado: (2016)

Durable Resolution of Severe Psoriasis in a Patient Treated with Pentostatin for Hairy Cell Leukemia: A Case Report
por: Alsuliman, Tamim, et al.
Publicado: (2017)

Epitranscriptomics modifier pentostatin indirectly triggers Toll-like receptor 3 and can enhance immune infiltration in tumors
por: Tusup, Marina, et al.
Publicado: (2022)

Fludarabine inhibits type I interferon-induced expression of the SARS-CoV-2 receptor angiotensin-converting enzyme 2
por: Xiu, Huiqing, et al.
Publicado: (2021)

Allogeneic Stem Cell Transplantation for Patients with Advanced Hematological Malignancies: Comparison of Fludarabine-based Reduced Intensity Conditioning versus Myeloablative Conditioning
por: Kim, Inho, et al.
Publicado: (2007)

Simultaneous clinical resolution of focal segmental glomerulosclerosis associated with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab
por: Arampatzis, Spyridon, et al.
Publicado: (2011)

Prognostic role of CD4 T-cell depletion after frontline fludarabine, cyclophosphamide and rituximab in chronic lymphocytic leukaemia
por: Gauthier, Martin, et al.
Publicado: (2019)

Conditioning with Fludarabine-Busulfan versus Busulfan-Cyclophosphamide Is Associated with Lower aGVHD and Higher Survival but More Extensive and Long Standing Bone Marrow Damage
por: He, Xin, et al.
Publicado: (2016)

Conditioning with 10 Gy Total Body Irradiation, Cyclophosphamide, and Fludarabine without ATG Is Associated with Improved Outcome of Cord Blood Transplantation in Children with Acute Leukemia
por: Cho, Hee Won, et al.
Publicado: (2021)

A BRAF-Negative Classic Hairy Cell Leukemia Patient with Long-Lasting Complete Remission after Rituximab and Pentostatin
por: Gozzetti, Alessandro, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_q1g9pd6v7nja0tgf6irihc8ic6